Just doing my annual 2017 investment review. As the person who seems to support BLT management strategy the most, I have a couple of points/questions to ask you:
AMD was a notable omission from the AGM address, seems like it has fallen by the wayside prior to impending Q4 POC milestone. We really need good data to progress investment to IND? Where is your confidence level on this program?
In terms of investment, how do you feel that management chose to expend critical funds in 2017 on progressing the HepB program only for it to be shelved months later (I seriously doubt a partner will come forward because it is a complex multi pronged therapy being proposed).
At the management level, Hollaway has gone, Francis has been moved to non Exec role, Nant are at the investment and management helm, change is in train. I am unsure where the funding will come from for head neck and shoulder Cancer & the other programs given the company's position.
Overall you seem to have great respect for the current management team's ability to deliver (OPMD success for me is a highlight).
Looking ahead, where are your confidence levels BLT management will deliver positively in 2018?
BLT Price at posting:
18.0¢ Sentiment: Hold Disclosure: Held
